article · European Journal of Pharmaceutical Sciences
A newly synthesised pyrazole derivative, designated as compound AD732, has been evaluated for its therapeutic effectiveness and safety profile in pain and inflammation management. In laboratory and animal models, the compound was compared against standard anti-inflammatory medications, indomethacin and celecoxib. Evaluations included rat paw oedema, cotton pellet granuloma, hyperalgesia, hot plate responses, and in vitro cyclooxygenase selectivity. Compound AD732 demonstrated stronger anti-inflammatory and pain-relieving effects than the standard comparator drugs. Furthermore, acute exposure revealed no ulcer-causing damage to the stomach and only minimal impact on kidney function. In laboratory assays, AD732 showed less potent COX-2 inhibition than celecoxib, pointing towards potentially reduced cardiovascular risk. Overall, the findings suggest that the molecule is an effective and potentially safer candidate for treating inflammatory and painful disorders.
Standard pain and anti-inflammatory drugs frequently cause serious adverse effects, including stomach ulcers, kidney damage, and cardiovascular complications. Discovering alternative compounds that provide potent pain relief while reducing these toxic risks is vital for individuals suffering from chronic inflammatory conditions. Demonstrating therapeutic potency alongside an improved gastric and renal safety profile marks a valuable step in developing better-tolerated treatments.
This research represents early-stage preclinical drug discovery that could interest pharmaceutical developers seeking safer non-steroidal anti-inflammatory therapeutics. The compound serves as a lead candidate for treating chronic pain and inflammation with lower gastrointestinal and renal risks. Because the evidence is limited to in vitro assays and acute animal testing, extensive pharmacokinetic, toxicity, and clinical trials will be necessary before commercial development is possible.
AI-generated from the published abstract. Always read the original work before citing.
The development of new COX-2 inhibitors with analgesic and anti-inflammatory efficacy as well as minimal gastrointestinal, renal and cardiovascular toxicity, is of vital importance to patients suffering from chronic course pain and inflammatory conditions. This study aims at evaluating the therapeutic activity and adverse drug reactions associated with the use of the newly synthesized pyrazole derivative, compound AD732, E-4-[3-(4-methylphenyl)-5-hydroxyliminomethyl-1H-pyrazol-1-yl]benzenesulfonamide, as compared to indomethacin and celecoxib as standard agents. Anti-inflammatory activity was assessed using carrageenan-induced rat paw edema and cotton pellet granuloma tests; formalin-induced hyperalgesia and hot plate tests were done to study analgesic activity. In vitro tests to determine COX-1/COX-2 selectivity and assessment of renal and gastric toxicity upon acute exposure to AD732 were also conducted. Compound AD732 exhibited promising results; higher anti-inflammatory and analgesic effects compared to standard agents, coupled with the absence of ulcerogenic effects and minimal detrimental effects on renal function. Additionally, compound AD732 was a less potent inhibitor of COX-2 in vitro than celecoxib, which may indicate lower potential cardiovascular toxicity. It may be concluded that compound AD732 appears to be a safer and more effective molecule with promising potential for the management of pain and inflammation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.ejps.2021.106080
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
